Critical Survey: Unicycive Therapeutics (NASDAQ:UNCY) and Rapport Therapeutics (NASDAQ:RAPP)

Rapport Therapeutics (NASDAQ:RAPP) and Unicycive Therapeutics (NASDAQ:UNCY) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, valuation, profitability, dividends, risk and analyst recommendations.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Rapport Therapeutics and Unicycive Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rapport Therapeutics	1	0	10	2	3.00
Unicycive Therapeutics	1	1	5	0	2.57

Rapport Therapeutics presently has a consensus price target of $62.86, indicating a potential upside of 31.73%. Unicycive Therapeutics has a consensus price target of $18.75, indicating a potential upside of 259.88%. Given Unicycive Therapeutics’ higher possible upside, analysts clearly believe Unicycive Therapeutics is more favorable than Rapport Therapeutics.

Institutional & Insider Ownership

40.4% of Unicycive Therapeutics shares are held by institutional investors. 12.5% of Rapport Therapeutics shares are held by insiders. Comparatively, 6.0% of Unicycive Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Rapport Therapeutics and Unicycive Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rapport Therapeutics	N/A	N/A	-$111.48 million	($3.04)	-15.70
Unicycive Therapeutics	N/A	N/A	-$26.56 million	($1.75)	-2.98

Rapport Therapeutics is trading at a lower price-to-earnings ratio than Unicycive Therapeutics, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Rapport Therapeutics has a beta of 0.97, indicating that its share price is 3% less volatile than the S&P 500. Comparatively, Unicycive Therapeutics has a beta of 1.79, indicating that its share price is 79% more volatile than the S&P 500.

Profitability

This table compares Rapport Therapeutics and Unicycive Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Rapport Therapeutics	N/A	-29.02%	-27.37%
Unicycive Therapeutics	N/A	-91.50%	-61.47%

About Rapport Therapeutics

Rapport Therapeutics Inc. is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc. is based in BOSTON.

About Unicycive Therapeutics

Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.